Treatment responses for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC) are often short lived and are marred with recurrences. The introduction of adjuvant PD-1 inhibitors has demonstrated significant improvement in both, response rates, and duration of response. For patients with high-risk resectable disease, adjuvant treatments have not demonstrated an ability to reduce recurrence risk. However, there is an opportunity in the neoadjuvant setting to alter recurrence risk. Here we dem-onstrate two cases of neoadjuvant treatment of cSCC and MCC with impressive results. J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7043e.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.36849/JDD.7043 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!